Specialist equity research for
ASX life sciences and healthcare

Bridge Life Sciences analyses ASX-listed therapeutics, diagnostics, medical technology and digital health companies, connecting scientific and clinical evidence with commercial prospects, funding requirements and valuation.

Independent of capital raisings

Every report free to read

Clear reasoning and disclosures

Understand the science. Assess the investment case.

Life sciences investing requires more than a headline result. Clinical evidence, regulatory pathways, market opportunity and access to capital all shape the investment case.
‍
Bridge Life Sciences brings these elements together in clear, evidence-based equity research, helping investors assess the opportunities, risks and milestones that matter.  

Connecting the science and the financial case

01

Scientific and clinical analysis

We examine a company's study designs, clinical results and regulatory pathways to assess what the evidence supports – and where uncertainty remains.

02

Commercial and financial assessment

We assess the company's market opportunity, competition and funding requirements, and assess the drivers of the investment case to develop our valuation.

03

Clear reasoning and disclosures

We explain the assumptions behind our analysis as well as the principal risks, and disclose how the research is funded.

Approach

Equity research across life sciences and healthcare

Therapeutics

Diagnostics

Medical technology

Digital health

In-depth coverage that develops over time – not just a single report.

Start with the research.

Explore our latest company research and commentary on ASX life sciences and healthcare.

General information only. See Legal and Disclaimer.